Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...
After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...
Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...
Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...
From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ahead.
Two moon landers, one from Japan's ispace and another from U.S. space firm Firefly, began their journeys into space on Wednesday (January 15) with SpaceX's unusual double moonshot launch, underscoring ...
BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...
Shareholders request Human Rights Due Diligence to determine whether pharma companies do everything they can to increase drug ...
The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...